Services Design Development Scientific Advice Project Management QA – Quality Assurance Monitoring Clinical Performance Data Management/eTrials Biostatistics Medical Writing Expert Statement Expertise Pharmacokinetics BA/BE Interactions Oncological trials Ophthalmological trials Inhalatives Transdermal Therapeutic Systems Children Sexual Hormones Therapeutic Expertise Clinical Development Phase I Phase II / Proof of Concept Phase III in OTC Phase III Non-Interventional Magnetic Marker Monitoring Medical Devices Nutrition Studies Clinical Pharmacology Unit Location Plan Capacity Technical Monitoring Ophthalmology Gynaecology Intensive Assessment Unit Clean Room Area Archive About Us Goals and Visions Our Experts Science Quality Library Presentations Library Publications Locations Career News 3rd GBHI conference – program is online Who is a healthy subject? German Pharm-Tox Summit 2017 in Heidelberg 2nd part of Introductory Course in Exploratory Medicines Development scheduled for February 2017 Introductory Course in Exploratory Medicines Development – taking place in our offices in Oberursel! 2nd Global Bioequivalence Harmonisation Initiative – a great success Probanden The SocraTec Family SocraTec C&S SocraMetrics Cooperations
NIS Ocular tolerability FDA Clinical development program Metered dose inhaler IMPD EMA Steady state Investigators brochure Safety Pragmatism Transdermal therapeutic system Spacious archive Early phase Local tolerability Dermal irritation Allergy Ophthalmologist Charcoal MDI Pharmacology Dry powder inhaler Patient recruitment CRF Dose linearity Sensitisation trials Biopharmaceutics Clinical trials Data Validation Plan CDISC Eye disease ADAM Efficacy Bioavailability CDASH DUS Inspection Sequential designs DPI MCID Authorities PAES Good Clinical Practice Quality Assurance Monitoring Phase IIb trials Product development Post authorisation AGAH Source Data Verification Dry eye Feasibility Non interventional Phase IIa trials CRA Referral system Cough Immunogenicity OTC CDSIC Degeneration Phase I Unit Statistical Analysis Plan Biopharmaceutical Bioequivalence Postmenopausal women Hypothalamic Auditing Elpro Copyright Rhine Main area CRO Ophthalmological trials Ovulation inhibition Uveitis Ophthalmology Drug Drug Interaction Standard operating procedure Informed Consent Procedure Subcontractor qualification Intensive assessment station Data Management Plan DFI WinNonlin Phase III Female adolescents Central surveillance system Sore throat Asthma HPA axis Paediatricians Design development Pilot study Audit HRT SDV Patients Healthy subjects Life cycle management Clinical study IVIVC Pituitary Oncologic network First in human Thuringia Pharmacodynamic studies PASS Absorption windows Data management Edema SOP based GLP Expert Scientific advice Experience TTS Phase I Creativity Protocol development Endpoint Adrenocortical Legal Information Hormone replacement therapy Lung Xerostomia ANVISA IEC Biosimilars MMM Standardisation Pulse oximetry plethysmography Project Management IB HTA SocraTec C&S Statistical programming Highly variable drugs Centralised procedure Quality Legal representative Phase II Contraception Biometrics Phase IV US FDA Common cold Consultancy Quality Management System US CFR 21 Part 11 ICF Pharmacokintetics Clinical Monitoring Children Inhalatives Cardiovascular surveillance Glaucoma Competence Network GCP training In vitro in vivo correlation Training Slit lamp microscopy DDI Sample size estimation Anaesthesiologist Pharmacokinetics Statistical services Protocol COPD Oncology Macular Absorption Clinical pharmacology unit Recruitment rates Patch SAS Scientific expertise Oncological patients Drug Food Interaction CDM GCP Database Axis Patch adhesion FIM Gynaecological trials  
 
Menu

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
All fine on front page